
Satralizumab Reduces Risk of Severe NMOSD Relapse
- Uncategorized
- Admin COUPONS
- September 14, 2020
Compared with placebo, satralizumab reduces the risk of severe relapse in patients with neuromyelitis optica spectrum disorder (NMOSD). Medscape Medical News
Read More
Please login to post a comment.